Tag: Tolcapone

An estimated 2–3% of the population aged 65 and older suffers from Parkinson's disease (PD), a neurodegenerative disorder affecting movement. For many patients, managing motor fluctuations and 'wearing-off' periods is a key treatment goal, making an understanding of what are the most common COMT inhibitors essential for maximizing the effectiveness of levodopa therapy.

Approximately 2-3% of the population aged 65 or older are affected by Parkinson's disease, a condition often managed using therapies that include a COMT inhibitor. This class of drugs is a crucial tool in the pharmacological management of Parkinson's, specifically for addressing the 'wearing-off' periods that many patients experience.